Microvascular Dysfunction in Heart Transplantation is Associated with Altered Cardiomyocyte Mitochondrial Structure and Unimpaired Excitation-contraction Coupling

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 May 31

PMID 38820336

Authors

Felix Hohendanner

Markus Boegner

Judith Huettemeister

Kun Zhang

Stephan Dreysse

Christoph Knosalla

Volkmar Falk

Felix Schoenrath

Isabell Anna Just

Philipp Stawowy

Affiliations

Soon will be listed here.

Abstract

Introduction: Microvascular dysfunction (MVD) is a hallmark feature of chronic graft dysfunction in patients that underwent orthotopic heart transplantation (OHT) and is the main contributor to impaired long-term graft survival. The aim of this study was to determine the effect of MVD on functional and structural properties of cardiomyocytes isolated from ventricular biopsies of OHT patients.

Methods: We included 14 patients post-OHT, who had been transplanted for 8.1 years [5.0; 15.7 years]. Mean age was 49.6 ± 14.3 years; 64% were male. Coronary microvasculature was assessed using guidewire-based coronary flow reserve(CFR)/index of microvascular resistance (IMR) measurements. Ventricular myocardial biopsies were obtained and cardiomyocytes were isolated using enzymatic digestion. Cells were electrically stimulated and subcellular Ca2+ signalling as well as mitochondrial density were measured using confocal imaging.

Results: MVD measured by IMR was present in 6 of 14 patients with a mean IMR of 53±10 vs. 12±2 in MVD vs. controls (CTRL), respectively. CFR did not differ between MVD and CTRL. Ca2+ transients during excitation-contraction coupling in isolated ventricular cardiomyocytes from a subset of patients showed unaltered amplitudes. In addition, Ca2+ release and Ca2+ removal were not significantly different between MVD and CTRL. However, mitochondrial density was significantly increased in MVD vs. CTRL (34±1 vs. 29±2%), indicating subcellular changes associated with MVD.

Conclusion: In-vivo ventricular microvascular dysfunction post OHT is associated with preserved excitation-contraction coupling in-vitro, potentially owing to compensatory changes on the mitochondrial level or due to the potentially reversible cause of the disease.

References

Hohendanner F, Maxwell J, Blatter L . Cytosolic and nuclear calcium signaling in atrial myocytes: IP3-mediated calcium release and the role of mitochondria. Channels (Austin). 2015; 9(3):129-38. PMC: 4594594. DOI: 10.1080/19336950.2015.1040966. View

Bode D, Semmler L, Wakula P, Hegemann N, Primessnig U, Beindorff N . Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF. Cardiovasc Diabetol. 2021; 20(1):7. PMC: 7792219. DOI: 10.1186/s12933-020-01208-z. View

Heinzel F, Hohendanner F, Jin G, Sedej S, Edelmann F . Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. J Appl Physiol (1985). 2015; 119(10):1233-42. PMC: 4652334. DOI: 10.1152/japplphysiol.00374.2015. View

Zhou H, Hu S, Jin Q, Shi C, Zhang Y, Zhu P . Mff-Dependent Mitochondrial Fission Contributes to the Pathogenesis of Cardiac Microvasculature Ischemia/Reperfusion Injury via Induction of mROS-Mediated Cardiolipin Oxidation and HK2/VDAC1 Disassociation-Involved mPTP Opening. J Am Heart Assoc. 2017; 6(3). PMC: 5524036. DOI: 10.1161/JAHA.116.005328. View

Dhital K, Azeka E, Colvin M, DePasquale E, Farrero M, Garcia-Guereta L . The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023; 42(5):e1-e141. DOI: 10.1016/j.healun.2022.10.015. View

Fearon W, Balsam L, Farouque H, Caffarelli A, Robbins R, Fitzgerald P . Novel index for invasively assessing the coronary microcirculation. Circulation. 2003; 107(25):3129-32. DOI: 10.1161/01.CIR.0000080700.98607.D1. View

Koch A, Geil-Bierschenk C, Rieker R, Dengler T, Sack F, Schirmacher P . Morphometric changes of the right ventricle in the first two weeks after clinical heart transplantation: analysis of myocardial biopsies from patients with complicated versus uncomplicated course. Eur J Cardiothorac Surg. 2006; 30(2):370-8. DOI: 10.1016/j.ejcts.2006.04.034. View

Bode D, Lindner D, Schwarzl M, Westermann D, Deissler P, Primessnig U . The role of fibroblast - Cardiomyocyte interaction for atrial dysfunction in HFpEF and hypertensive heart disease. J Mol Cell Cardiol. 2019; 131:53-65. PMC: 7065048. DOI: 10.1016/j.yjmcc.2019.04.016. View

Bode D, Wen Y, Hegemann N, Primessnig U, Parwani A, Boldt L . Oxidative Stress and Inflammatory Modulation of Ca Handling in Metabolic HFpEF-Related Left Atrial Cardiomyopathy. Antioxidants (Basel). 2020; 9(9). PMC: 7555173. DOI: 10.3390/antiox9090860. View

10.

Fearon W, Kobayashi Y . Invasive Assessment of the Coronary Microvasculature: The Index of Microcirculatory Resistance. Circ Cardiovasc Interv. 2017; 10(12). DOI: 10.1161/CIRCINTERVENTIONS.117.005361. View

11.

Liu I, Lin T, Wang S, Yen C, Li C, Kuo H . Long-term administration of Western diet induced metabolic syndrome in mice and causes cardiac microvascular dysfunction, cardiomyocyte mitochondrial damage, and cardiac remodeling involving caveolae and caveolin-1 expression. Biol Direct. 2023; 18(1):9. PMC: 9987103. DOI: 10.1186/s13062-023-00363-z. View

12.

Hohendanner F, Bode D, Primessnig U, Guthof T, Doerr R, Jeuthe S . Cellular mechanisms of metabolic syndrome-related atrial decompensation in a rat model of HFpEF. J Mol Cell Cardiol. 2018; 115:10-19. DOI: 10.1016/j.yjmcc.2017.12.012. View

13.

Hohendanner F, Ljubojevic S, MacQuaide N, Sacherer M, Sedej S, Biesmans L . Intracellular dyssynchrony of diastolic cytosolic [Ca²⁺] decay in ventricular cardiomyocytes in cardiac remodeling and human heart failure. Circ Res. 2013; 113(5):527-38. DOI: 10.1161/CIRCRESAHA.113.300895. View

14.

Merz C, Pepine C, Walsh M, Fleg J . Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. Circulation. 2017; 135(11):1075-1092. PMC: 5385930. DOI: 10.1161/CIRCULATIONAHA.116.024534. View

15.

Vancheri F, Longo G, Vancheri S, Henein M . Coronary Microvascular Dysfunction. J Clin Med. 2020; 9(9). PMC: 7563453. DOI: 10.3390/jcm9092880. View

16.

Marin W, Marin D, Ao X, Liu Y . Mitochondria as a therapeutic target for cardiac ischemia‑reperfusion injury (Review). Int J Mol Med. 2021; 47(2):485-499. PMC: 7797474. DOI: 10.3892/ijmm.2020.4823. View

17.

Lee J, Jung J, Hwang D, Park J, Fan Y, Na S . Coronary Flow Reserve and Microcirculatory Resistance in Patients With Intermediate Coronary Stenosis. J Am Coll Cardiol. 2016; 67(10):1158-1169. DOI: 10.1016/j.jacc.2015.12.053. View

18.

Sucato V, Novo G, Evola S, Novo S . Coronary microvascular dysfunction in patients with diabetes, hypertension and metabolic syndrome. Int J Cardiol. 2015; 186:96-7. DOI: 10.1016/j.ijcard.2015.03.213. View

19.

Mehta P, Huang J, Levit R, Malas W, Waheed N, Merz C . Ischemia and no obstructive coronary arteries (INOCA): A narrative review. Atherosclerosis. 2022; 363:8-21. PMC: 9840845. DOI: 10.1016/j.atherosclerosis.2022.11.009. View

20.

Chin K, Qin C, May L, Ritchie R, Woodman O . New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury. Curr Drug Targets. 2015; 18(15):1689-1711. DOI: 10.2174/1389450116666151001112020. View